Pediatric Reauthorization In Senate Hits Pothole From Cost Offset For Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
A BPCA/PREA reauthorization bill in the Senate is similar to a bi-partisan House bill that has been incorporated into House Energy and Commerce Committee Republicans’ discussion draft of comprehensive user fee legislation, but Senate HELP committee drafters appear to need to find a “pay-for” before including the provisions.
You may also be interested in...
Pediatric Studies Delayed Mostly By FDA Red Tape, Companies Say
FDA posts non-compliance letters and responses from three sponsors that failed to meet deadlines for submitting reports for trials of four drugs in children; more than 70 firms have had their deadlines extended.
CBO Says Senate User Fee Package Will Decrease Direct Spending
While drug development incentives will increase federal health care program spending, other provisions designed to allow lower-cost drugs on the market faster are expected to reduce costs.
User Fee Legislation Revs Through Senate Mark-up, But House Bill Goes Back Into The Shop
Senate health committee defers action on several potentially contentious issues, with members hoping to resolve differences over FDA’s authorities on imports, shortages, foreign data and track-and-trace before the bill goes to the floor, possibly in May. Meanwhile, the House postpones its mark-up in an effort to craft a more bipartisan bill, and now will try to push the user fee package to the floor during an upcoming four-day marathon session.